New oral GLP-1 weight loss medicine guide
Foundayo UK: Orforglipron Weight Loss Pill Explained
Foundayo® is the brand name for orforglipron, a once-daily oral GLP-1 weight loss tablet developed by Eli Lilly. It has been approved in the United States, and is now currently licensed in the UK.
This guide explains what Foundayo is, how orforglipron works, how it compares with Mounjaro and Wegovy, what clinical trials show, and what UK patients should know about availability and safe treatment options.
Written by: Live Well Weight Loss Pharmacy Team
Clinically reviewed by: Moazma Ahmed, Pharmacist Independent Prescriber, GPhC 2069977
Last reviewed: August 2026
Next review due: September 2027
Quick Answer: Is Foundayo Available in the UK?
No. Foundayo, also known by its active ingredient orforglipron, is not currently approved by the MHRA and cannot be legally prescribed or supplied by UK pharmacies at this time. Foundayo has been approved in the United States as an oral GLP-1 medicine for adults with obesity or overweight with weight-related health conditions. UK availability would require MHRA authorisation and appropriate UK prescribing guidance before it could be offered by regulated providers.Important: Foundayo (orforglipron) is now approved in the UK for weight management. It is a prescription-only medicine and should only be obtained from a legitimate UK pharmacy following an appropriate clinical assessment.
Foundayo at a Glance
| Question | Current answer |
|---|---|
| Brand name | Foundayo |
| Active ingredient | Orforglipron |
| Medicine type | Oral small-molecule GLP-1 receptor agonist |
| How is it taken? | Once-daily tablet |
| Is it an injection? | No. It is a tablet. |
| US status | FDA-approved for weight management in eligible adults. |
| UK status | Now MHRA-approved and available from UK pharmacies. |
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed for weight management. Unlike Mounjaro and Wegovy, which are injections, Foundayo is taken as a tablet. Orforglipron is known as a small-molecule GLP-1 medicine. This is important because many existing GLP-1 medicines are peptide-based injections, while orforglipron is designed to be taken orally without the same administration process as injectable treatments. Interest in Foundayo is high because many patients would prefer a tablet over a weekly injection.How Does Orforglipron Work?
Orforglipron works by activating the GLP-1 receptor. GLP-1 is a hormone pathway involved in appetite, fullness, digestion, and blood sugar control.Reduces hunger
GLP-1 activity can help reduce appetite and make it easier to eat smaller portions.
Increases fullness
It may help patients feel fuller for longer after meals.
Supports blood sugar control
GLP-1 medicines can help improve insulin response and blood sugar regulation.
Foundayo vs Mounjaro vs Wegovy
Foundayo, Mounjaro, and Wegovy all belong to the wider field of incretin-based weight loss treatments, but they differ in active ingredient, route of administration, and UK availability.| Treatment | Active ingredient | How it is taken | Receptor activity | UK status |
|---|---|---|---|---|
| Foundayo | Orforglipron | Once-daily tablet | GLP-1 | Approved for weight management in suitable patients. |
| Wegovy | Semaglutide | Once-weekly injection | GLP-1 | Approved for weight management in suitable patients. |
| Mounjaro | Tirzepatide | Once-weekly injection | GIP + GLP-1 | Approved for weight management in suitable patients. |
| Retatrutide | Retatrutide | Once-weekly injection in trials | GIP + GLP-1 + glucagon | Investigational and not currently UK-approved. |
How Much Weight Loss Did Orforglipron Show in Trials?
In the ATTAIN-1 Phase 3 trial in adults with obesity or overweight, orforglipron showed statistically significant weight loss compared with placebo over 72 weeks.| Trial / evidence | Population | Duration | Reported result |
|---|---|---|---|
| ATTAIN-1 | Adults with obesity or overweight without diabetes | 72 weeks | Highest dose produced an average weight loss of 27.3 lb, or 12.4%. |
| ATTAIN-2 | Adults with obesity or overweight and type 2 diabetes | 72 weeks | Reported significant weight loss, A1C reduction, and cardiometabolic improvements. |
| ACHIEVE-3 | Adults with type 2 diabetes | Head-to-head diabetes trial | Orforglipron 36mg lowered A1C more than oral semaglutide 14mg in the reported trial. |
Is Foundayo as Strong as Mounjaro?
Foundayo and Mounjaro should not be treated as interchangeable. They are different medicines with different mechanisms, formats, and evidence bases. Mounjaro is an injectable GIP and GLP-1 medicine that is already approved in the UK for suitable patients. Foundayo is an oral GLP-1 medicine that has been approved in the US but is now UK-approved. Trial results suggest orforglipron can support meaningful weight loss, but Mounjaro has generally shown larger average weight loss in obesity trials. The potential advantage of Foundayo is its tablet format rather than superior weight loss.How Is Foundayo Taken?
Foundayo is taken as a once-daily tablet. Lilly has described it as an oral GLP-1 pill that can be taken without the food or water restrictions associated with some other oral GLP-1 medicines. This may be important for patients because some oral GLP-1 medicines require strict timing around food, drink, and other medicines. Foundayo’s simpler dosing could make it easier for some patients to fit treatment in the UK.UK note: Dosing instructions for UK patients can now be confirmed because the medicine is approved by the MHRA and UK product information is published.
Foundayo Side Effects and Safety
The adverse-event profile reported in trials was broadly consistent with other GLP-1 receptor agonist medicines. Side effects are most commonly gastrointestinal, particularly when starting or increasing dose.Commonly reported side effects
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Indigestion
- Reduced appetite
Safety questions for UK use
- Final UK product information
- Contraindications and cautions
- Drug interactions
- Long-term tolerability
- Use in patients with diabetes
- Real-world discontinuation rates
Can You Buy Foundayo Online in the UK?
UK pharmacies can now supply Foundayo or orforglipron because it is now licensed in the UK. Unregulated sellers may offer fake, contaminated, incorrectly dosed, imported, or unsafe products. There may also be no clinical assessment, no prescriber oversight, and no reliable safety monitoring.Red flags for unsafe Foundayo or orforglipron sellers
- Claims that Foundayo which sound unreasonable.
- No prescription or clinical assessment required
- Social media, WhatsApp, Telegram, or marketplace sellers
- No UK pharmacy registration details
- No prescriber details
- No clear source or manufacturer information
- Very low prices or “research chemical” wording
- Imported tablets without UK regulatory approval
When Will Foundayo Be Available in the UK?
Foundayo (orforglipron) is now approved and available in the UK as a private prescription treatment for weight management. It was authorised by the MHRA on 10 August 2026 and is a prescription-only medicine. Patients must complete an appropriate clinical assessment with a qualified UK prescriber before treatment can be supplied. Foundayo is not currently routinely available through the NHS. NICE is assessing orforglipron for weight management, which may determine whether it is recommended for future NHS use.
What Can UK Patients Use Now?
If you are interested in Foundayo because you want medical support for weight loss, there are already approved options available in the UK for suitable patients.Mounjaro
A once-weekly injectable GIP and GLP-1 medicine used for weight management in suitable patients.
Wegovy
A once-weekly injectable GLP-1 medicine used for weight management in suitable patients.
Lifestyle and maintenance support
Long-term success also depends on nutrition, activity, sleep, follow-up, side effect management, and weight maintenance planning.
Frequently Asked Questions About Foundayo and Orforglipron
Looking for Approved Weight Loss Treatment?
Foundayo is currently available in the UK. If you want to explore approved options such as Mounjaro or Wegovy, complete an eligibility check and our clinical team will review your information.
Check EligibilityRelated Guides
References
- Eli Lilly and Company. FDA approval announcement for Foundayo orforglipron, 2026.
- Eli Lilly and Company. ATTAIN-1 Phase 3 orforglipron obesity results, 2025.
- New England Journal of Medicine. Orforglipron, an oral small-molecule GLP-1 receptor agonist, 2025.
- Eli Lilly and Company. ATTAIN-2 Phase 3 orforglipron results in adults with type 2 diabetes and obesity or overweight, 2025.
- Eli Lilly and Company. ACHIEVE-3 head-to-head data with oral semaglutide in type 2 diabetes, 2026.
- MHRA and UK regulatory guidance for prescription-only and approved weight loss medicines.
